This undated photo issued by the University of Oxford shows of vial of coronavirus vaccine developed by AstraZeneca and Oxford University, in Oxford, England. Pharmaceutical company AstraZeneca said Monday Nov. 23, 2020, that late-stage trials showed its coronavirus vaccine was up to 90% effective, giving public health officials hope they may soon have access to a vaccine that is cheaper and easier to distribute than some of its rivals. (University of Oxford/John Cairns via AP)

This undated photo issued by the University of Oxford shows of vial of coronavirus vaccine developed by AstraZeneca and Oxford University, in Oxford, England. Pharmaceutical company AstraZeneca said Monday Nov. 23, 2020, that late-stage trials showed its coronavirus vaccine was up to 90% effective, giving public health officials hope they may soon have access to a vaccine that is cheaper and easier to distribute than some of its rivals. (University of Oxford/John Cairns via AP)

VIDEO: How do the leading COVID vaccines differ? And what does that mean for Canada?

All three of the drug companies are incorporating novel techniques in developing their vaccines

On Monday AstraZeneca became the third pharmaceutical company this month to announce promising results from a late-stage coronavirus vaccine clinical trial, joining Pfizer and Moderna as the leading candidates for developing an effective prevention for COVID-19.

While all promise a suitable vaccine can be rolled out within the coming months, they differ slightly in efficacy, delivery and other components.

So how do we judge the leading candidates so far, and how might they impact a vaccine rollout program in Canada?

The Canadian Press asked Kelly Grindrod, an associate professor at the University of Waterloo’s School of Pharmacy, and Dr. Earl Brown, a virology and microbiology expert at the University of Ottawa, to break down those questions.

HOW DO THEY WORK?

All three of the drug companies are incorporating novel techniques in developing their vaccines, with Pfizer and Moderna using messenger RNA (mRNA) and AstraZeneca using a non-replicating viral vector.

AstraZeneca’s vaccine, developed with Oxford University, takes a chimpanzee cold virus that’s not harmful to humans and “hides” pieces of the coronavirus in it, Grindrod explained. Non-replicating means the virus won’t actually reproduce throughout the body.

“It shows our cells how to make the coronavirus spike protein so that our bodies can actually have an immune response to it,” she said.

Brown explained it as a “dummy virus” that has essentially had its genes stripped and replaced with the spike protein gene for the coronavirus. The vaccine makes an mRNA molecule from the genome and that molecule makes the protein, he said.

“The protein is put on the cell, the immune system recognizes it and makes antibodies — therefore immunity.”

The mRNA vaccines are similar, but structurally different with Brown simplifying it by saying Pfizer and Moderna “put the RNA right into your arm.”

“Their vaccine is a synthetically-produced mRNA packaged in a fat coating,” he said. “So they inject that into your muscles, that little fat gloms onto your cells, fuses with them and becomes part of the cell and dumps that mRNA into your cell. And then the mRNA is translated into protein.”

Grindrod said both vaccine methods “show us the genetic component” our cells need to make the antibodies.

“It’s just really how it’s delivered,” she added.

HOW EFFECTIVE ARE THEY?

AstraZeneca says its vaccine was up to 90 per cent effective when a half dose was followed by a full dose a month later. Another method, where two full doses were distributed a month apart, showed to be 62 per cent effective.

Moderna said last week that preliminary data showed a 94.5 per cent efficacy, and Pfizer, the first to share its initial results earlier this month, upped theirs from 90 to 95 after releasing final trial results last week.

While the medical journal “The Lancet” did review some of AstraZeneca’s results, Grindrod says to remember that most of the efficacy claims from the clinical trials are from press releases based off preliminary data.

“Now what we’re waiting for is the actual study, the full published, peer review that you can see and compare efficacy and safety and how they measured it,” she said, adding she expects peer-reviewed studies on the vaccines to emerge soon.

“Things are coming at much different timelines than we’re used to.”

Another factor that’s still unknown is how long immunity lasts, and whether we will need booster vaccines in the future.

WHAT ARE THE HURDLES FACING DISTRIBUTION?

All three of the leading vaccine candidates require two doses, injected roughly one month apart, and there could be challenges in getting people back to a doctor or pharmacy to receive their second dose.

Grindrod said tracking will become particularly important with a two-dose vaccine, especially if AstraZeneca goes forward with injecting different amounts of the vaccine per dose. Rollout can become even more complicated when there’s a surge for the vaccine, as we saw this year with the flu shot.

“You have to track who got which vaccine, which dose, and make sure they come back three to four weeks later,” she said.

Where AstraZeneca could have the upper hand in distribution, however, is in its storage temperature. The company says its vaccine can be stored in a fridge, unlike Moderna and Pfizer, which require freezing temperatures due to the instability of the mRNA, Brown says.

Pfizer’s vaccine needs to be stored at minus-70 C, while Moderna’s needs a temperature around minus-20 C — about the same as a regular freezer.

“For really ultra-low temperature freezers, you find those in hospitals and research laboratories, but not many other places,” Brown said. “So we aren’t prepared for (a vaccine that requires) ultra low freezers.”

READ MORE: 3rd major COVID-19 vaccine shown to be effective and cheaper

ARE THERE ANY SIDE EFFECTS?

Side effects for all three vaccines have been minimal — things like sore arms, fatigue and headaches that generally don’t last long — and Brown says the presence of those reactions are a good thing.

“When you’re vaccinating, you’re stimulating an immune response, and those are immune-regulated things,” he said. “So a sore arm reaction is good, because that means it’s working for you.”

More safety data, which can only be garnered from monitoring trial participants over a longer term, is needed to judge further, he says.

WHAT’S NEXT, AND WHAT DOES IT MEAN FOR CANADA?

The Food and Drug Administration (FDA) is meeting to discuss Pfizer’s emergency use authorization request on Dec. 10, which means a vaccine rollout could happen in the United States within the next month.

But the vaccines would need approval from Health Canada in order to get them here.

Health Canada’s website says it will review authorization submissions from companies to determine “evidence of safety, efficacy and manufacturing quality for each vaccine.”

Canada locked in a supply of potential vaccine candidates when it signed agreements with a number of pharmaceutical companies, including AstraZeneca, Pfizer and Moderna months ago, and that should accelerate a rollout when ready.

READ MORE: First COVID vaccines could arrive in U.S. on Dec. 12

But the actual time frame will depend on when these drug companies can show enough safety data to move forward, Brown said.

Grindrod expects a viable candidate to be approved quickly after safety and efficacy can be shown.

“We might see early 2021 and it’s not clear whether that’s January or February or around that time,” she said. “From there, as we get more doses and more vaccines are approved, then we may see a broader population getting vaccinated. But it’s hard to say when that will happen.”

Melissa Couto Zuber, The Canadian Press


Like us on Facebook and follow us on Twitter.

Want to support local journalism during the pandemic? Make a donation here.

Coronavirusvideo

Just Posted

A tent housing a mobile vaccination clinic. (Interior Health/Contributed)
Over 5K jabbed at Interior Health mobile COVID-19 vaccine clinics

The clinics have made stops in more than 40 communities since launching last week

Provincial Health Officer Dr. Bonnie Henry talks about B.C.’s plan to restart the province during a press conference at Legislature in Victoria, Tuesday, May 25, 2021. THE CANADIAN PRESS/Chad Hipolito
Interior Health COVID-19 cases falling slower than the rest of B.C.

More than a third of provincial cases announced Thursday came from the Interior

A tent housing a mobile vaccination clinic. (Interior Health/Contributed)
Second dose vaccinations accelerating throughout region: Interior Health

To date, more than 675,000 doses have been administered throughout the region

Okanagan Lake (File photo)
Thompson-Okanagan ready to welcome back tourists

The Thompson-Okanagan Tourism Association expects this summer to be a busy one

Aerial view of a wildfire at 16 Mile, 11 kilometres northwest of Cache Creek, that started on the afternoon of June 15. (Photo credit: BC Wildfire Service)
Wildfire at 16 Mile now being held

Wildfire started on the afternoon of June 15 at 16 Mile, east of Highway 97

Marco Mendicino, Minister of Immigration, Refugees and Citizenship during a press conference in Ottawa on Thursday, May 13, 2021. THE CANADIAN PRESS/Sean Kilpatrick
Canada to welcome 45,000 refugees this year, says immigration minister

Canada plans to increase persons admitted from 23,500 to 45,000 and expedite permanent residency applications

The George Road wildfire near Lytton, B.C., has grown to 250 hectares. (BC Wildfire Service)
Drone sighting halts helicopters fighting 250 hectares of B.C. wildfire

‘If a drone collides with firefighting aircraft the consequences could be deadly,’ says BC Wildfire Service

A dose of the Pfizer-BioNTech COVID-19 vaccine is pictured at a vaccination site in Vancouver Thursday, March 11, 2021. THE CANADIAN PRESS/Jonathan Hayward
NACI advice to mix vaccines gets varied reaction from AstraZeneca double-dosers

NACI recommends an mRNA vaccine for all Canadians receiving a second dose of a COVID-19 vaccine

A aerial view shows the debris going into Quesnel Lake caused by a tailings pond breach near the town of Likely, B.C., Tuesday, Aug. 5, 2014. THE CANADIAN PRESS/Jonathan Hayward
Updated tailings code after Mount Polley an improvement: B.C. mines auditor

British Columbia’s chief auditor of mines has found changes to the province’s requirements for tailings storage facilities

A North Vancouver man was arrested Friday and three police officers were injured after a 10-person broke out at English Bay on June 19, 2021. (Youtube/Screen grab)
Man arrested, 3 police injured during 10-person brawl at Vancouver beach

The arrest was captured on video by bystanders, many of whom heckled the officers as they struggled with the handcuffed man

Patrick O’Brien, a 75-year-old fisherman, went missing near Port Angeles Thursday evening. (Courtesy of U.S. Coast Guard)
Search for lost fisherman near Victoria suspended, U.S. Coast Guard says

The 75-year-old man was reported missing Thursday evening

Bruce Springsteen performs at the 13th annual Stand Up For Heroes benefit concert in support of the Bob Woodruff Foundation in New York on Nov. 4, 2019. (Greg Allen/Invision/AP)
Canadians who got AstraZeneca shot can now see ‘Springsteen on Broadway’

B.C. mayor David Screech who received his second AstraZeneca dose last week can now attend the show

New research suggests wolves can be steered away from the endangered caribou herds they prey on by making the man-made trails they use to hunt harder to move along. THE CANADIAN PRESS/Nathan Denette
Culling cutlines, not B.C. wolves, key to preserving caribou herds: researcher

The government has turned to killing hundreds of wolves in an effort to keep caribou around

Most Read